These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11212262)

  • 21. The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration.
    Casati A; Zimmermann VS; Benigni F; Bertilaccio MT; Bellone M; Mondino A
    J Immunol; 2005 Mar; 174(6):3317-25. PubMed ID: 15749863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
    Zhang W; He L; Cao X
    Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.
    Shimizu K; Fields RC; Giedlin M; Mulé JJ
    Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2268-73. PubMed ID: 10051630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
    Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
    Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A high-affinity T-helper epitope enhances peptide-pulsed dendritic cell-based vaccine.
    Li A; Xiong S; Lin Y; Liu R; Chu Y
    DNA Cell Biol; 2011 Nov; 30(11):883-92. PubMed ID: 21612399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of antitumor immunity using bone marrow-generated dendritic cells.
    Porgador A; Snyder D; Gilboa E
    J Immunol; 1996 Apr; 156(8):2918-26. PubMed ID: 8609412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
    Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
    Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intradermal immunization with combined baculovirus and tumor cell lysate induces effective antitumor immunity in mice.
    Kawahara M; Takaku H
    Int J Oncol; 2013 Dec; 43(6):2023-30. PubMed ID: 24101126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery.
    Asavaroengchai W; Kotera Y; Mulé JJ
    Proc Natl Acad Sci U S A; 2002 Jan; 99(2):931-6. PubMed ID: 11792864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates.
    Ju DW; Tao Q; Lou G; Bai M; He L; Yang Y; Cao X
    Cancer Res; 2001 May; 61(9):3735-40. PubMed ID: 11325846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.
    Jonuleit H; Giesecke-Tuettenberg A; Tüting T; Thurner-Schuler B; Stuge TB; Paragnik L; Kandemir A; Lee PP; Schuler G; Knop J; Enk AH
    Int J Cancer; 2001 Jul; 93(2):243-51. PubMed ID: 11410873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.
    Bedrosian I; Mick R; Xu S; Nisenbaum H; Faries M; Zhang P; Cohen PA; Koski G; Czerniecki BJ
    J Clin Oncol; 2003 Oct; 21(20):3826-35. PubMed ID: 14551301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
    Porgador A; Gilboa E
    J Exp Med; 1995 Jul; 182(1):255-60. PubMed ID: 7540653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo.
    De Smedt T; Smith J; Baum P; Fanslow W; Butz E; Maliszewski C
    J Immunol; 2002 Jan; 168(2):661-70. PubMed ID: 11777959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
    Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
    Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.